One Week of Magnesium Supplementation Lowers IL-6, Perceived Pain and Increases Post Exercise Blood Glucose in Response to Downhill Running

Sponsor

University of Worcester (Other)

Overall Status

Completed

CT.gov ID

NCT04216836

Collaborator

Beijing Sport Uninversity (Other), Coventry University (Other)

Enrollment

Location

Arms

8.1

Actual Duration (Months)

1.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study investigated the effect of magnesium supplementation on exercise performance and functional recovery in recreational endurance athletes in conjunction with measures of blood glucose, lactate, IL-6 and sIL-6R.

Condition or Disease	Intervention/Treatment	Phase
Magnesium Deficiency	Dietary Supplement: Magnesium oxide Dietary Supplement: Placebo	N/A

Detailed Description

Magnesium status can directly affect circulating glucose concentrations both during and post exercise. In addition, magnesium supplementation has been shown to reduce circulating IL-6 concentrations post exercise in humans. It is conceivable that such observations are linked through the role of IL-6 in glucose regulation, possibly in combination with sIL-6R. Together, magnesium intake may have the potential to effect exercise performance and recovery through glucose availability. This in turn may be connected to the production of IL-6 and sIL-6R which have been established to influence exercise fatigue and perception of pain (muscle soreness).

Study Design

Study Type:

Interventional

Actual Enrollment :

9 participants

Allocation:

Randomized

Intervention Model:

Crossover Assignment

Masking:

Double (Participant, Investigator)

Primary Purpose:

Prevention

Official Title:

One Week of Magnesium Supplementation Lowers IL-6, Perceived Pain and Increases Post Exercise Blood Glucose in Response to Downhill Running

Actual Study Start Date :

Jun 28, 2018

Actual Primary Completion Date :

Mar 1, 2019

Actual Study Completion Date :

Mar 1, 2019

Arms and Interventions

Arm	Intervention/Treatment
Experimental: High magnesium diet (SUP condition) Participants followed a low magnesium diet <260mg/day and consumed 500 mg/day of magnesium oxide. This was separated into 3 capsules, which were consumed at 6 hr intervals each day (8am, 2pm and 8pm). The supplementation period was 1 week.	Dietary Supplement: Magnesium oxide Magnesium capsule
Experimental: Low magnesium diet (CON condition) Participants followed a low magnesium diet <260mg/day and consumed 500 mg/day of placebo (cornflour). This was separated into 3 capsules, which were consumed at 6 hr intervals each day (8am, 2pm and 8pm). The supplementation period was 1 week.	Dietary Supplement: Placebo Cornflour capsule manufactured to mimic the 166.6 mg magnesium capsule.

Arm

Intervention/Treatment

Experimental: High magnesium diet (SUP condition)

Participants followed a low magnesium diet <260mg/day and consumed 500 mg/day of magnesium oxide. This was separated into 3 capsules, which were consumed at 6 hr intervals each day (8am, 2pm and 8pm). The supplementation period was 1 week.

Dietary Supplement: Magnesium oxide

Magnesium capsule

Experimental: Low magnesium diet (CON condition)

Participants followed a low magnesium diet <260mg/day and consumed 500 mg/day of placebo (cornflour). This was separated into 3 capsules, which were consumed at 6 hr intervals each day (8am, 2pm and 8pm). The supplementation period was 1 week.

Dietary Supplement: Placebo

Cornflour capsule manufactured to mimic the 166.6 mg magnesium capsule.

Outcome Measures

Primary Outcome Measures

Downhill 10 km treadmill time trial performance [1 day]
Maximal 10 km time trial performance on a treadmill
24 hr post exercise maximal force testing of the dominant leg on the isokinetic dynamometer [1 day]
Maximal force produced from the dominant leg (eccentric and concentric) on an isokinetic dynamometer.

Secondary Outcome Measures

Glucose [up to 2 days]
Capillary blood samples at rest, during, immediately post, 1 hr post and 24 hrs post 10 km downhill time-trial. A Biosen analyser was used to analyse glucose concentrations.
Interleukin-6 [up to 2 days]
Venous blood samples at rest, immediately post, 1hr post and 24 hrs 10 km downhill time trial. Enzyme-linked immunosorbent assays were used to analyse interleukin-6.
Soluble interleukin-6 receptor [up to 2 days]
Venous blood samples at rest, immediately post, 1hr post and 24 hrs 10 km downhill time trial. Enzyme-linked immunosorbent assays were used to analyse soluble interleukin-6.
Perceived muscle soreness [up to 4 days]
A 10cm visual analogue scale was used to assess perceived muscle soreness, the scale started at 0 (no pain) and finished at 10 (unbearable pain)
Lactate [up to 2 days]
Capillary blood samples at rest, during, immediately post, 1 hr post and 24 hrs post 10 km downhill time-trial. A Biosen analyser was used to analyse lactate concentrations.
Creatine kinase [up to 2 days]
Venous blood samples at rest, immediately post, 1hr post and 24 hrs 10 km downhill time trial. A Reflotron analyser was used to analyse creatine kinase concentrations.

Eligibility Criteria

Criteria

Ages Eligible for Study:

20 Years to 35 Years

Sexes Eligible for Study:

Male

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Regular recreational runner, running around 3 times per week
Capable of running 10 km in ~ 40 minutes.

Exclusion Criteria:

Any signs or symptoms of cardiovascular issues.
Any recent form of injury or illness.
Currently, or in the last 3 months, have consumed multivitamin supplements
Currently, or in the last 3 months, have consumed anti-inflammatory medications.